- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05769595
Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)
February 21, 2024 updated by: Merck Sharp & Dohme LLC
A Single-dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-2060 in Japanese Older Participants With End-stage Renal Disease on Dialysis.
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of MK-2060 after a single dose intravenous (IV) administration in Japanese older participants with end stage renal disease (ESRD) on dialysis.
There is no primary hypothesis for this study.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
17
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Toll Free Number
- Phone Number: 1-888-577-8839
- Email: Trialsites@merck.com
Study Locations
-
-
-
Fukuoka, Japan, 815-8555
- Japanese Red Cross Fukuoka Hospital ( Site 1214)
-
Yamagata, Japan, 990-0834
- Yamagata Tokushukai Hospital ( Site 1201)
-
-
Aichi
-
Kasugai, Aichi, Japan, 486-8510
- Kasugai Municipal Hospital ( Site 1203)
-
Nagoya, Aichi, Japan, 455-8530
- Chubu Rosai Hospital ( Site 1202)
-
Nagoya, Aichi, Japan, 457-8511
- Kojunkai Daido Hospital ( Site 1207)
-
-
Gunma
-
Maebashi, Gunma, Japan, 371-0046
- Jomo Ohashi Clinic ( Site 1210)
-
-
Ibaraki
-
Kasama, Ibaraki, Japan, 309-1793
- Ibaraki Prefectural Central Hospital ( Site 1211)
-
-
Kanagawa
-
Kamakura, Kanagawa, Japan, 247-8533
- Shonan Kamakura General Hospital ( Site 1205)
-
-
Nagano
-
Matsumoto, Nagano, Japan, 390-1401
- Matsumoto City Hospital ( Site 1209)
-
-
Oita
-
Beppu, Oita, Japan, 874-0937
- Keiaikai Nakamura Hospital ( Site 1213)
-
-
Shiga
-
Kusatsu, Shiga, Japan, 525-8585
- Omi Fureai Hospital ( Site 1204)
-
-
Tokyo
-
Ota, Tokyo, Japan, 146-8531
- Ikegami General Hospital ( Site 1206)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Japanese descent with all 2 biological parents of Japanese descent
- On hemodialysis (HD) or hemodiafiltration (HDF) with single-pool Kt/V (spKt/V) ≥1.2, using arteriovenous (AV) fistula or AV graft ≥3 months prior to Screening 1 at a healthcare center, and is on the same dialysis regimen ≥2 weeks prior to Screening 1
- Be judged to plan to continue or anticipate the use of the current AV fistula or AV graft until the poststudy visit
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- On peritoneal dialysis or other dialysis modalities except for HD and HDF
- History of deep vein thrombosis or pulmonary embolism
- History of vascular access thrombosis within 1 month prior to Screening 1
- Personal or family history of bleeding disorder
- History of GI bleeding, duodenal polyps or active gastroduodenal ulcer within 5 years prior to Screening 1, or history of severe hemorrhoidal bleed within 3 months prior to Screening 1
- History of frequent epistaxis within 3 months prior to Screening 1 or active gingivitis
- At the time of screening or predose, planned significant dental procedures, or other planned surgical procedures within duration of participation in the trial
- History of receiving any human immunoglobulin preparation such as intravenous immunoglobulin (IVIG) or a brand of Rho(D) immune globulin (RhoGAM) within 1 year prior to Screening 1
- History of receiving any biological therapy within 3 months prior to Screening 1, or vaccination within 1 month prior to the dose of study intervention
- Requires or anticipates requiring the use of following prohibited medications until the poststudy visit: anticoagulants, antiplatelet medications and non-steroidal anti-inflammatory drugs (NSAIDs)
- Participated in another investigational study within 1 month prior to Screening 1
- Has blood coagulation test (activated partial thromboplastin time [aPTT] or prothrombin time [PT]) above 1.2X upper limit of normal (ULN) at Screening 1 from the central laboratory for safety
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MK-2060
Participants receive MK-2060 50 mg via a single intravenous (IV) infusion over 60-minutes.
|
Lyophilized powder diluted in normal saline for IV infusion
|
Placebo Comparator: Placebo
Participants receive a single IV saline infusion over 60 minutes.
|
IV infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Experience an Adverse Event (AE)
Time Frame: Up to approximately 164 days
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug.
The number of participants who experience an AE will be reported.
|
Up to approximately 164 days
|
Number of Participants Who Discontinue Study Due to an AE
Time Frame: Up to approximately 164 days
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug.
The number of participants who discontinue study due to an AE will be reported.
|
Up to approximately 164 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Concentration-Time Curve of MK-2060 From Time 0 to Infinity (AUC 0-inf)
Time Frame: Day 1-3: Predose and 1, 12, 24, 48 and 52 hours postdose; once daily on Days 5, 12, 15, 22, 60, 90, 150: postdose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
|
Blood samples will be collected at specified intervals for the determination of AUC0-inf.
AUC0-inf is defined as the area under the concentration-time curve of pembrolizumab from time zero to infinity.
|
Day 1-3: Predose and 1, 12, 24, 48 and 52 hours postdose; once daily on Days 5, 12, 15, 22, 60, 90, 150: postdose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
|
Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to Last (AUC0-last)
Time Frame: Day 1-3: Predose and 1, 12, 24, 48 and 52 hours postdose; once daily on Days 5, 12, 15, 22, 60, 90, 150: postdose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
|
Blood samples will be collected at specified intervals for the determination of AUC0-last.
AUC0-last is defined as the area under the plasma concentration-time curve from time zero to time of last measurable concentration of MK-2060.
|
Day 1-3: Predose and 1, 12, 24, 48 and 52 hours postdose; once daily on Days 5, 12, 15, 22, 60, 90, 150: postdose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
|
Area Under the Concentration-Time Curve of MK-2060 From Time 0 to 168 Hours Postdose (AUC0-168)
Time Frame: Predose and 1, 12, 24, 48, 52, 96, and 168 hours postdose
|
Blood samples will be collected at specified intervals for the determination of AUC0-168.
AUC0-168 is defined as the area under the concentration-time curve of MK-2060 from time zero to 168 hours.
|
Predose and 1, 12, 24, 48, 52, 96, and 168 hours postdose
|
Maximum Concentration (Cmax) of MK-2060
Time Frame: Day 1-3: Predose and 1, 12, 24, 48 and 52 hours postdose; once daily on Days 5, 12, 15, 22, 60, 90, 150: postdose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
|
Blood samples will be collected at specified intervals for the determination of Cmax.
Cmax is defined as the maximum concentration of MK-2060 reached.
|
Day 1-3: Predose and 1, 12, 24, 48 and 52 hours postdose; once daily on Days 5, 12, 15, 22, 60, 90, 150: postdose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
|
Concentration at 168 Hours (C168) Postdose of MK-2060
Time Frame: Predose and 1, 12, 24, 48, 52, 96, and 168 hours postdose
|
Blood samples will be collected at specified intervals for the determination of C168.
C168 is defined as the maximum concentration of MK-2060 reached at 168 hours postdose.
|
Predose and 1, 12, 24, 48, 52, 96, and 168 hours postdose
|
Time to Maximum Concentration (Tmax) of MK-2060
Time Frame: Day 1-3: Predose and 1, 12, 24, 48 and 52 hours postdose; once daily on Days 5, 12, 15, 22, 60, 90, 150: postdose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
|
Blood samples will be collected at specified intervals for the determination of Tmax.
Tmax is defined as time to the maximum concentration of MK-2060 reached.
|
Day 1-3: Predose and 1, 12, 24, 48 and 52 hours postdose; once daily on Days 5, 12, 15, 22, 60, 90, 150: postdose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
|
Time of the Last Measurable Plasma Concentration (Tlast) of MK-2060
Time Frame: Day 1-3: Predose and 1, 12, 24, 48 and 52 hours postdose; once daily on Days 5, 12, 15, 22, 60, 90, 150: postdose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
|
Blood samples will be collected at specified intervals for the determination of Tlast.
Tlast is defined as the time to the last measurable concentration of MK-2060 reached.
|
Day 1-3: Predose and 1, 12, 24, 48 and 52 hours postdose; once daily on Days 5, 12, 15, 22, 60, 90, 150: postdose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
|
Terminal Half-Life (t ½) of MK-2060
Time Frame: Day 1-3: Predose and 1, 12, 24, 48 and 52 hours postdose; once daily on Days 5, 12, 15, 22, 60, 90, 150: postdose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
|
Blood samples will be collected at specified intervals for the determination of t½.
t½ is defined as the time required to divide the MK-2060 plasma concentration by two after reaching pseudo-equilibrium, following a single dose of MK-2060.
|
Day 1-3: Predose and 1, 12, 24, 48 and 52 hours postdose; once daily on Days 5, 12, 15, 22, 60, 90, 150: postdose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
|
Clearance (CL) of MK-2060
Time Frame: Day 1-3: Predose and 1, 12, 24, 48 and 52 hours postdose; once daily on Days 5, 12, 15, 22, 60, 90, 150: postdose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
|
Blood samples will be collected at specified intervals for the determination of CL.
CL is the volume of plasma from which the study drug is completely removed per unit time.
|
Day 1-3: Predose and 1, 12, 24, 48 and 52 hours postdose; once daily on Days 5, 12, 15, 22, 60, 90, 150: postdose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
|
Volume of Distribution (Vz) of MK-2060
Time Frame: Day 1-3: Predose and 1, 12, 24, 48 and 52 hours postdose; once daily on Days 5, 12, 15, 22, 60, 90, 150: postdose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
|
Blood samples will be collected at specified intervals for the determination of Vz.
Vz is the apparent volume of distribution during the terminal phase.
|
Day 1-3: Predose and 1, 12, 24, 48 and 52 hours postdose; once daily on Days 5, 12, 15, 22, 60, 90, 150: postdose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
|
Change From Baseline in Activated Partial Thromboplastin Time (aPTT)
Time Frame: Baseline and up to 150 days
|
Blood samples will be collected for the determination of aPTT.
Change from baseline in aPTT up to 150 days will be reported.
|
Baseline and up to 150 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Medical Director, Merck Sharp & Dohme LLC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 14, 2023
Primary Completion (Actual)
February 15, 2024
Study Completion (Actual)
February 15, 2024
Study Registration Dates
First Submitted
March 3, 2023
First Submitted That Met QC Criteria
March 3, 2023
First Posted (Actual)
March 15, 2023
Study Record Updates
Last Update Posted (Actual)
February 22, 2024
Last Update Submitted That Met QC Criteria
February 21, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2060-012
- MK-2060-012 (Other Identifier: Merck)
- jRCT2041230025 (Registry Identifier: jRCT)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Failure, Chronic
-
Centre Hospitalier Universitaire DijonTerminatedEnd-stage Chronic Kidney FailureFrance
-
Angiodynamics, Inc.TerminatedChronic Kidney Disease | Acute Kidney Injury | Acute Renal Failure | Renal Failure Chronic Contrast InducedUnited States
-
Baxter Healthcare CorporationRecruitingAcute Kidney Failure | Chronic Kidney FailureChina
-
Texas A&M UniversityWithdrawnChronic Kidney FailureUnited States
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
Hopital Jean MinjozUnknownCardiac Surgical Procedures | Preoperative KIDNEY FAILURE, CHRONIC | Postoperative KIDNEY FAILURE, ACUTEFrance
-
Nantes University HospitalNot yet recruiting
-
Ozge AKBABAAtaturk UniversityCompletedChronic Kidney FailureTurkey
-
Chinese PLA General HospitalCompletedKidney Failure,ChronicChina
-
Fatma Alzahraa Mohamed Ibrahim Hassan HaggagUnknown
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States